GENEVA - Monday, June 3rd 2013 [ME NewsWire]

(BUSINESS WIRE)-- Union Bancaire Privée, UBP SA ("UBP”), one of Switzerland’s leading private banks, is pleased to announce that it has agreed to acquire Lloyds Banking Group’s ("Lloyds”) International Private Banking business. This is a key step in the execution of UBP’s strategy to grow its global presence and to expand its private banking activities.

This acquisition further boosts UBP’s standing both in Switzerland and in its core growth markets, such as the Middle East and Latin America. Once the requisite regulatory licences have been granted, Monaco and Gibraltar will become part of UBP’s global footprint. The transaction will increase UBP’s assets under management, which stood at CHF 83.2 billion as at 30 April 2013, by more than CHF 10 billion. Following this acquisition, UBP will continue to be one of the best-capitalised private banks with a Tier 1 ratio above 30%.

Lloyds’ expertise in the fields of pri ... Read more »

Dubaï, Émirats Arabes Unis - Lundi 3 Juin 2013 [ME NewsWire]

Le groupe Rolman, une société dont le siège se trouve à Dubaï et qui est considérée comme étant un des plus grands et des plus reconnus distributeurs de roulements et des services techniques pour applications spécialisées au Moyen Orient et en Afrique, annonce l’emménagement du groupe dans un nouveau siège ultramoderne d’une plus grande superficie à la Zone Franche de Jebel Ali(JAFZA) à Dubaï. Dr. Abdulla Al Banna, vice-président responsable  des ventes commerciales et M. Akram Muazzen, PDG du Rolman Group ont signé le contrat de location à JAFZA. Le déménagement du siège actuel à JAFZA vers le nouveau siège est censé commencer durant le troisième trimestre de l’année en cours.

Le centre opérationnel et logistique ultramoderne du Rolman Group, résident de longue date à JAFZA, a ouvert ses p ... Read more »

Dubai, United Arab Emirates - Sunday, June 2nd 2013 [ME NewsWire]

The Rolman Group, a Dubai-based company, which is one of the largest and most established distributors of bearings and related technical application-specific services in the Middle East and Africa, announces its move into its new larger state-of-the-art headquarters in the Jebel Ali Free Zone Authority (JAFZA) in Dubai. The lease agreement was signed in JAFZA by Dr. Abdulla Al Banna, Vice President of Commercial Sales and Mr. Akram Muazzen, CEO of the Rolman Group. The move from its current headquarter location in JAFZA to this new headquarters is expected to begin in the third quarter this year.  

A long-time resident in JAFZA, the Rolman Group’s state-of-the-art operations and logistics center opened in 2004. This 5,000 square meter facility in JAFZA is the current home of the Rolman Group’s headquarters. "We have long since realized the value of being located in the UAE and have therefore establishe ... Read more »

Results from LUX-Lung 6, together with previously reported LUX-Lung 3 data, substantiate the efficacy and safety of afatinib* in lung cancer patients with EGFR mutations when compared with standard chemotherapies

INGELHEIM, Germany - Sunday, June 2nd 2013 [ME NewsWire]

(BUSINESS WIRE)-- Data from Boehringer Ingelheim’s LUX-Lung 6 trial, presented at the official American Society of Clinical Oncology (ASCO) Annual Conference, demonstrate that patients treated with the novel, investigational compound afatinib* lived for almost one year before their tumour started to grow again, compared to less than half a year for those on standard chemotherapy (gemcitabine/cisplatin). Tumour assessment was based on independent review of the data showing progression-free survival (PFS) of 11.0 months for afatinib* and PFS of 5.6 months for chemotherapy.1 In addition, 47% of afatinib*-treated patients were alive and progression-free after one year of treatment compared to only 2% on chemot ... Read more »

RESEARCH TRIANGLE PARK, N.C - Saturday, June 1st 2013 [ME NewsWire]

(BUSINESS WIRE)-- In advance of the American Society of Clinical Oncology (ASCO) Annual Meeting, Quintiles today announced the release of its perspective on two areas of focus for clinical oncologists – the impact of patient selection in early-phase studies and the use of biomarkers in the treatment of hematologic malignancies.

The first of these reports, Tomorrow’s Path to Improved Early-Phase Oncology Drug Development, explores the importance of key elements to maximize quality and efficiency of go/no-go decisions in early-phase studies. As the understanding of the biology of cancer becomes more sophisticated and generates more opportunities, fundamental challenges caused by the complexities of this group of diseases are becoming more evident. Molecular profiling and leveraging molecular selection of patients has the potential to significantly improve the quality of early decisions in oncology drug deve ... Read more »

CHICAGO - Dimanche 2 Juin 2013 [ME NewsWire]

(BUSINESS WIRE)--Les résultats de la première étude multicentrique de grande envergure évaluant la radiothérapie interne sélective (SIRT) utilisant les microsphères SIR-Spheres® chez des patients âgés de 70 ans et plus ont été présentés aujourd’hui lors du Congrès annuel de la Société américaine de cancérologie clinique (American Society of Clinical Oncology, ASCO). Selon les chercheurs, l’utilisation de microsphères SIR-Spheres chez des patients âgés atteints d’un cancer colorectal avec métastases au foie non résécables apparaît être aussi efficace et aussi bien tolérée que chez des patients plus jeunes.1 Les conclusions ont été publiées par le chercheur principal de l’étude MORE, le Dr Andrew S. Kennedy, F.A.C.R.O., directeur de la recherche en radio-oncologie à l ... Read more »

RESEARCH TRIANGLE PARK, Caroline du Nord - Dimanche 2 Juin 2013 [ME NewsWire]

(BUSINESS WIRE)--En prévision de la réunion annuelle de l'American Society of Clinical Oncology (ASCO), Quintiles a annoncé aujourd'hui la publication de ses perspectives concernant deux domaines de recherche pouvant intéresser les oncologues cliniques : l'impact de la sélection des patients lors des phases précoces des études et l'utilisation de biomarqueurs dans le traitement des hémopathies malignes.

Le premier de ces rapports, Tomorrow’s Path to Improved Early-Phase Oncology Drug Development (La voie à suivre pour améliorer le développement des médicaments oncologiques en phase précoce), analyse les éléments essentiels susceptibles de maximiser, en phase précoce, la qualité et l'efficacité de la prise de décision concernant la poursuite ou non des études. Alors ... Read more »

ME Newswire

Dubai, United Arab Emirates - Saturday, June 1st 2013

Cellogique Corporation and Colorescience are pleased to announce their new partnership for the distribution of a revolutionary line of mineral makeup in the Middle East and Turkey.

Colorescience boasts "makeup that does more,” by combining the art of makeup with the science of skincare. This cutting edge line of makeup is comprised of high quality ingredients and minerals, infused with vitamins and antioxidants to help protect and nourish the skin while creating a flawless complexion. Colorescience products take care to avoid harmful ingredients including mineral oils, perfumes, talc, alcohol, dyes, preservatives, or emulsifiers. This means that Colorescience products promote healthy skin and are noncomedogenic.

"Colorescience products will be a great and complimentary addition to our extensive line of Obagi products.” Said Mazen F. Youssef, president and CEO of Cellogique Corporation. "The c ... Read more »

– First Presentation of Interim Phase 1/2 Data Reported in Pediatric Patients with Relapsed or Refractory Hodgkin Lymphoma or relapsed or refractory Systemic Anaplastic Large Cell Lymphoma -

CHICAGO & OSAKA, Japan - Saturday, June 1st 2013 [ME NewsWire]

2013 ASCO Annual Meeting

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502) today announced interim data from a Phase 1/2, open-label, multicenter study with ADCETRIS® (brentuximab vedotin) in pediatric patients diagnosed with CD30-positive relapsed or refractory Hodgkin lymphoma (HL) or relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). Data were presented from the Phase 1 portion of the study, which evaluated the safety, maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D), and pharmacokinetics (PK) of ADCETRIS. The results were reported during a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting held May 31 – June 4, ... Read more »

Dubai, United Arab Emirates - Saturday, June 1st 2013 [ME NewsWire]

Cellogique Corporation and Croma Princess are happy to announce the expansion of distribution of Croma Princess fillers and mesotherapy to include Saudi Arabia and the United Arab Emirates.

Croma Princess suggests an alternative to plastic surgery with their innovative and sophisticated fillers and mesotherapy. Croma Princess’ revolutionary hyaluronic dermal filler is a sterile, colorless, and homogenized gel implant used to relax facial wrinkles, folds, and scars. The hyaluronic face mesotherapy treatment is a sterile, transparent gel that hydrates and rejuvenates the skin while also making it more elastic. As these treatments are nonsurgical and noninvasive, patients have the ability to resume with daily activity immediately. In addition to these benefits, Croma Princess’ fillers and mesotherapy boast "immediate and natural effects.”

"The distribution of Croma Princess fillers and mesotherapy wil ... Read more »